I didn’t mean for this website to go as basic as this, quite the opposite, but apparently there’s still a huge need for basic stuff for basic people. And we can’t really advance much without covering the basics properly.
Not much else to add, besides our motto: “Don’t believe what we say, research what we say!”
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Best part: the admission comes from a court trial that has recently been concluded, then put a lid on. I discovered this accidentally, while following other leads.
Please contemplate this most spectacular paragraph and then I’ll give you all the background info you need:
Regarding factual material within the document, the court finds that “[t]he CDC does not . . . justify its withholding based on inextricable intertwining of facts and opinions.” “Rather, it defends the withholding because the facts about COVID-19 were changing frequently, and therefore any facts in the Media Strategy are ‘no more than . . . hypotheses advanced but later revised or rejected altogether.'” “The CDC states that releasing such ‘seemingly factual statements’ would ’cause damage both to the agency – by contradicting and/or undercutting the more reliable information that it ultimately released – and to the public, by creating confusion and potentially sowing mistrust in the guidance provided by the CDC and other Federal agencies.'” The court finds that “Defendants cite no law for the validity of such a justification under FOIA . . . and the Court is aware of none.” Moreover, the deliberative process privilege focuses on whether disclosure would ‘expose an agency’s decisionmaking process in such a way as to discourage candid discussion within the agency and thereby undermine the agency’s ability to perform its functions.‘” “The CDC does not argue that disclosure of the facts would chill the CDC’s internal discussion.” “Therefore, the Court rejects the agency’s justification for withholding the factual portions of the document.”
The reason I call it a “boomerang throw” is because the case was obviously a politicized attack on Trump admin’s alleged dictatorial oversight on science. They meant to show CDC wants to do better and OrangeManBad is keeping them on a leash, preventing transparency. But the solution to it blew up in Biden’s lap, exposing more of CDC’s foul plays when they least needed another public image blow. I mean, could’ve blown up, if anyone made a fuss about this.
Below is how Deep State University aka Harvard presented the case in April 2020:
CDC Sued to Disclose Restrictions on Scientists’ Right to Speak
By Adam Toobin – Edited by Genie Gorbonosov
April 16, 2020
<< Complaint for Injunctive Relief, Knight Institute v. CDC (S.D.N.Y Apr. 2, 2020) (No. 20-2761), complaint hosted by the Knight Institute.
Demanding the Trump Administration make public any restrictions on when employees of the Centers for Disease Control and Prevention may speak to the public or the press, the Knight First Amendment Institute at Columbia University is suing to force compliance with an unanswered Freedom of Information Act request they filed on March 19.
The complaint follows an extended controversy over whether and to what extent governments may restrict public employees from speaking to the press on their personal views. Laden with free speech concerns, the issue demands heightened urgency in the context of a worldwide pandemic that has killed tens of thousands and sparked fierce debate about the role of political leaders and scientists in responding to the crisis.
Motivating the Knight Institute’s concern in this instance is a record of severe restrictions on the rights of government scientists to speak freely to the press. In 2017, Axios published an email from Jeffrey Lancashire, a public affairs officer, to the National Center for Health Statistics, announcing that for every employee of the CDC “any and all correspondence with any member of the news media, regardless of the nature of the inquiry, must be cleared through CDC’s Atlanta Communications Office.”
This policy may exacerbate fears that the White House has politicized the nation’s response to the pandemic and inhibited the voicing of alternate views that could shed light on the extent of the crisis, according to the Knight Institute’s complaint.
“According to recent news stories, scientists and health officials at the CDC must now coordinate with the Office of Vice President Mike Pence before speaking with members of the press or public about the pandemic,” the complaint reads. “These stories have raised concerns that public health experts who know most about the risks to the public are not being permitted to speak candidly and that the information the government is now conveying may be incomplete, inaccurate, or misleading.”
This lawsuit follows recent litigation that has raised questions about the current constitutional status of rights of public employees to speak to the press without official oversight. In 2006, the Supreme Court held in Garcetti v. Ceballos that speech by public employees should only receive First Amendment protection when they are communicating in their capacity as private individuals. However, in the 2014 case of Lane v. Franks, the Court held that “the mere fact that a citizen’s speech concerns information acquired by virtue of his public employment does not transform that speech into employee—rather than citizen—speech.”
Rather than facing doctrinal hurdles in overturning government restrictions on the right of public employees to speak, a recent law review article by Frank LoMonte, head of the Brechner Center for Freedom of Information, identifies the fact that public employees have had to put their careers and employment relationship in jeopardy in order to bring suit. LoMonte suggests that journalists and news organizations should have standing to challenge overbroad restrictions on the right of public employees to speak.
While still untested, the prospect suggests a new line of attack on the type of rules the CDC may be enforcing against its employees. The Knight Institute’s lawsuit may then be seen as the first step in raising a more fundamental question about the constitutionality of these restrictions.
On the alternative side, public health officials have also emphasized the importance of clear and trustworthy information reaching the public during a period of such acute national and international challenges. The spread of misinformation online has drawn particular concern and forced some social media platforms to take unprecedented steps to control what their users can see and share, including partnering with organizations like the CDC and the World Health Organization to verify the information blitzing around their sites. Multiple conflicting messages from government officials — not bound by tight central controls — could contribute to the public’s confusion.
Ultimately, the Knight Institute’s lawsuit focuses on a much more narrow question: Whether the government should be permitted to keep secret its rules for when government scientists may speak publicly. As the coronavirus pandemic enters a new month, long since having banished facets of everyday life once taken for granted, the issue takes on the weight of all those who worry everyday about the information they receive from the government and the media.>>
Fantastic presentation, Harvard! Now, you know what’s way more stunning? Let’s have a look at the full court decision on this!
Friday, September 17, 2021
Knight First Amendment Inst. at Columbia Univ. v. CDC, No. 20-2761, 2021 WL 4253299 (S.D.N.Y. Sept. 17, 2021) (Torres, J.)
Re: Request for certain records concerning coronavirus or Coronavirus Task Force, as well as records concerning communication with news media and public policies
Disposition: Denying defendants’ motion for summary judgment; granting in part and denying in part plaintiff’s motion for summary judgment
Litigation Considerations, Adequacy of Search: “The Court concludes that the CDC’s search for documents responsive to requests one and two was not reasonably likely to uncover all responsive documents.” First, the court finds that “the CDC improperly narrowed the scope of [its] search, and shall reconduct it in light of this order.” “Here, the plain language of the requests indicate that they encompass more than the CDC’s interpretation.” “Requests one and two seek records ‘relating to’ policies and procedures, and so are broader than merely the policies themselves.” Responding to plaintiff’s argument, the court finds that “courts have rejected the idea that including a specific request invalidates an overlapping broader request.” Second, the court finds that “‘FOIA requests are not a game of Battleship.'” “‘The requester should not have to score a direct hit on the records sought based on the precise phrasing of his request.'” The court explains that “an agency must search for synonyms or common variants of a term used in the request that are likely to be used in responsive documents, unless it can reasonably justify declining to use them.” “[T]he agency justifies its limitation of search terms as a means of ‘strik[ing] a balance between fully and completely capturing emails dealing with the subject matter of Plaintiff’s requests and eliminating the large number of nonresponsive emails captured by the first search.'” “But, an agency’s duty under FOIA is not to strike such a balance; it is to conduct a search reasonably calculated to uncover all relevant documents, unless such a search would be an undue burden.” Additionally, the court finds that “Plaintiff correctly observes that the agency’s affidavit does not give sufficient detail about how the search was conducted.” “[I]t does not specify how Boolean searches were used: for instance, if it searched for the two-word terms like ‘covid communication’ in quotes (producing only documents containing those two words in sequence), or not (producing documents with either one of those words anywhere in the document).” “Without such detail, the Court cannot conclude that the agency demonstrated that the search terms were reasonably calculated to uncover responsive documents.” Finally, the court finds that “CDC has given no reason it did not search the inboxes of the individuals identified by Plaintiff, which Plaintiff reasonably contends may contain responsive documents.” “Therefore, it was unreasonable of the CDC to omit those individuals likely to have responsive documents from the search.” Of specific note, the court finds that “Defendants . . . argue that the CDC’s search was reasonable despite the omission of [one individual], because the produced records demonstrate that her supervisor . . . ‘was included in all correspondence to or from [the omitted individual] concerning items 1 and 2 of Plaintiff’s request.'” “However, this logic does not hold: [the supervisor’s] inclusion on the emails uncovered by a search of her email inbox does not mean that [the omitted individual] did not send or receive other responsive emails which did not include [her supervisor].” “Therefore, it is reasonably likely that [the omitted individual] has other, undiscovered responsive documents, and must be included in a reasonable search.”
Exemption 5, Other Privileges: The court holds that “Defendants have not met their burden of demonstrating that the presidential communications privilege covers [two documents], given the scope of dissemination of those documents.” The court relates that the two documents are “a February 25, 2020 email authored by . . . President Donald J. Trump’s then-acting White House Chief of Staff[] and sent to ‘Senior Government Officials,’ described as a ‘[p]roposed coordinated media communication strategy for COVID-19 with designated speakers for various issues/topics,'” and “a February 25 and 27, 2020 email chain involving [the then-acting White House Chief of Staff], described as an ‘[u]pdate and elaboration of proposed coordinated media communication strategy for COVID-19.'” The court relates that “Plaintiff no longer disputes that these documents were properly authored by a member of the President’s staff.” “However, Plaintiff disputes whether these documents were kept sufficiently confidential for the privilege to apply.” The court finds that “[d]isclosure of the documents would not prevent the President from operating effectively.” “The media strategy of an executive agency is not a quintessential presidential power like the removal power; it is and was performed without presidential input.” “Nor would disclosing the documents undermine future presidential decision-making; as discussed below, the policies appear to have been forward-looking plans to coordinate strategy.” “And finally, because the policies were distributed to more than just the President’s closest advisors, his ability to communicate his final decisions privately was not implicated.” “Moreover, the documents were not treated as confidential for purposes of the privilege.” “The documents were also distributed throughout the Executive Branch, including to individuals whom Defendants have not established are covered by this privilege.” “Though Defendants state that the majority of the recipients were in the EOP, not all individuals in the EOP are within the narrow circle of the presidential communications privilege.” “Finally, the documents appear to have been distributed to some of the recipients for a non-advisory purpose.”
Exemption 5, Deliberative Process Privilege & Other Considerations: The court denies defendants’ motion for summary judgment regarding “a ’02/25 – 02/26/2020 Division of Global Migration and Quarantine email chain . . .’ and the information withheld within them[,] [specifically,] ‘[d]iscussion of how to apply 02/25/2020 EOP email to Senior Government Officials.'” The court finds that that material consists of “discussions of how to apply a binding policy, rather than conferring about developing that policy.” “Therefore, any discussion of its application was post-decisional, and outside the scope of the privilege.” The court relates that “Defendants . . . argue that [some of that material] was not an operative policy because on [a later date], a new email was sent, erasing the [earlier] framework.” “However, although the Document 9 policy may have been temporaru, it is still a final decision while in effect.” “In addition, the CDC has not sufficiently articulated a harm associated with disclosing [that material].” “Defendants merely assert that disclosure of some of the documents withheld under the deliberative process privilege ‘could cause harm by chilling future free exchange of ideas and opinions by agency leadership on similarly sensitive matters.'” “[T]his assertion is not specific enough to meet the FOIA requirements.”
Exemption 5, Deliberative Process Privilege & Litigation Considerations, “Reasonably Segregable” Requrements: Separately, the court considers a “a number of iterations of a document titled ‘CDC Communication and Media Strategy for the Coronavirus Disease 2019 Response.'” The court relates that “the CDC avers that [one of these iterations, the only one plaintiff still challenges,] was ‘revised and circulated to help frame ongoing deliberative discussions within CDC for anticipated consideration by CDC decisionmakers,’ but that no Media Strategy was ultimately decided upon.” “Plaintiff has identified a number of features of [the document] that suggest it is, at least, the closest to final version of the Media Strategy produced.” Additionally, the court notes that “[p]roduced documents discussing the Media Strategy also indicate that the goal was ‘to finalize the first iteration of this strategy document,’ . . . which indicates that the CDC intended to create an operative version, even if that version was to be updated.” Also, the court finds that “[t]he CDC also does not describe, specifically for Document 12, the author, its recipient, or those individuals’ relationships to each other and the decision-making process, details which have been considered ‘critical’ to a court’s analysis under the deliberative process privilege.” The court also relates that “Plaintiff argues that [the document] should not be withheld because it is a ‘messaging’ document.” “Though courts in this district are split over how to handle messaging documents, . . . the Court agrees that when considering documents ‘about how the agency should communicate its policies to people outside the agency,’ it must focus on ‘whether the drafts or communications reflect deliberations about what “message” should be delivered to the public about an already-decided policy decision, or whether the communications are of a nature that they would reveal the deliberative process underlying a not-yet-finalized policy decision.'” “On this record, the Court cannot determine if [the document at issue] is merely articulating how to discuss agency policy, or if it is itself an expression of the CDC’s ‘essential policymaking role.'” “Accordingly, the Court cannot yet decide whether [this document] falls into the deliberative process privilege.”
Regarding factual material within the document, the court finds that “[t]he CDC does not . . . justify its withholding based on inextricable intertwining of facts and opinions.” “Rather, it defends the withholding because the facts about COVID-19 were changing frequently, and therefore any facts in the Media Strategy are ‘no more than . . . hypotheses advanced but later revised or rejected altogether.'” “The CDC states that releasing such ‘seemingly factual statements’ would ’cause damage both to the agency – by contradicting and/or undercutting the more reliable information that it ultimately released – and to the public, by creating confusion and potentially sowing mistrust in the guidance provided by the CDC and other Federal agencies.'” The court finds that “Defendants cite no law for the validity of such a justification under FOIA . . . and the Court is aware of none.” Moreover, the deliberative process privilege focuses on whether disclosure would ‘expose an agency’s decisionmaking process in such a way as to discourage candid discussion within the agency and thereby undermine the agency’s ability to perform its functions.'” “The CDC does not argue that disclosure of the facts would chill the CDC’s internal discussion.” “Therefore, the Court rejects the agency’s justification for withholding the factual portions of the document.”
Updated November 4, 2021
You could start the Comedy Central Roast of CDC with that material. Hey, Rand Paul, where art thou?
“Science will win”.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Sometimes my memes are 3D. And you can own them. Or send them to someone. You can even eat some of them. CLICK HERE
THERE’S NO BETTER PREVENTION THAN SHARING THE KNOWLEDGE FASTER THAN THEY SHARE THEIR PROPAGANDA!
The original title of this article was URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: NIPAH VIRUS. I expanded the scope because in the meantime I learned they are ramping up propaganda for all three. These viruses have more things in common, as you will find out below.
You should actually begin with this earlier report:
To further develop the ChAd3 Ebola and Marburg vaccines, Sabin has entered into a Research Collaboration Agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. The Sabin Vaccine Institute, a non-profit organization founded in 1993, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin received more than $110 million for vaccine R&D programs from public and philanthropic funding sources, including the Bill & Melinda Gates Foundation, European Commission, Dutch Ministry of Foreign Affairs, Global Health Innovative Technology Fund and the Michelson Medical Research Foundation.
Washington DC, Oct. 21, 2021 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the third contract option, valued at $34.5 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.
In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million. This third contract option will enable continued nonclinical efficacy and safety studies, Phase 2 clinical trials in Africa, and vaccine manufacturing processes to ensure quality and safety.
In August, a case of Marburg disease was confirmed in the West African country of Guinea where the Ministry of Health officially declared an outbreak of Marburg.1 This recent case, as well as Marburg’s history of outbreaks and their potential for future devastating outbreaks, demonstrates that preventative measures are overdue to protect civilian populations, military personnel, first responders, health care workers and laboratory workers, both in the United States and abroad, against these emerging infectious diseases.
Ebola Sudan and Marburg viruses are closely related to Ebola Zaire virus, which has caused more than 2,200 deaths since 2018, leading the World Health Organization (WHO) to declare it a Public Health Emergency of International Concern. Like Ebola Zaire, Ebola Sudan and Marburg are among the world’s deadliest viruses, causing hemorrhagic fever with subsequent death in an average of 50 percent of cases.2,3
“Even as the world struggles with the COVID-19 pandemic, disease caused by Ebola Sudan and Marburg viruses continue to be a serious threat, as we have seen with the recent outbreak of Marburg in Guinea. We are grateful for BARDA’s continued support of Sabin’s efforts to advance vaccines against these deadly viruses,” said Sabin Chief Executive Officer Amy Finan. “We also thank our partners at the Vaccine Research Center of the NIH National Institute of Allergy and Infectious Diseases for their continued collaboration, and GSK for their earlier work on the candidates.”
The two candidate vaccines, based on GSK’s proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00055.
This above is the official Sabin Inst. press release, this below isn’t:
November 4, 2021 – The U.S. CDC published a Level Three Travel Advisory for the recent Ebola outbreak in the Beni Health Zone of the Democratic Republic of the Congo.
November 3, 2021 – The U.S. CDC vaccine advisory committee reviewed previous recommendation preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are: responding to an outbreak of Ebola Virus Disease (EVD), or work as health care personnel at federally designated Ebola treatment centers in the U.S., or work as laboratorians or other staff at biosafety level 4 facilities in the U.S.
November 2, 2021 – The WHO reported additional cases and deaths confirmed in the Ebola virus disease outbreak in the Democratic Republic of the Congo with two new health areas affected. A total of 394 people (67 primary care providers including nine high-risk contacts, nine contacts of contacts, and 49 probable contacts) have been vaccinated including 182 contacts of contacts, 125 probable contacts, and 87 high-risk contacts.
October 29, 2021 – A Research Article – Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomized, placebo-controlled Phase II clinical trial in Africa – was published by the journal PLOS Medicine. Conclusion – The Ad26.ZEBOV and MVA-BN-Filo combo vaccination were well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and an Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age.
October 27, 2021 – IAVI announced an award of up to US$126 million from the Biomedical Advanced Research and Development Authority to develop two recombinant vesicular stomatitis virus (rVSV)-vectored filovirus vaccine candidates. This award supports preclinical activities and includes options for clinical development up to and inclusive of a Phase II clinical trial of IAVI’s rVSV Sudan ebolavirus vaccine candidate (rVSVΔG-SUDV-GP). Optional work that would continue the development of IAVI’s Marburg virus vaccine candidate (rVSVΔG-MARV-GP) that is currently supported by the Defense Threat Reduction Agency of the U.S. Department of Defense could be funded at a later date.
“Vectored” means, most likely, mRNA or some other genetic / nanotech targeting technology.
October 20, 2021 – The WHO African Region reported 5 Ebola cases, and over 27,000 travelers have been screened in the DRC. Furthermore, over 116 people have been vaccinated.
October 17, 2021 – Africa News reported Ebola vaccinations started in Beni, DRC, after at least two people died due to the virus in October 2021. The WHO African Region Tweeted DRC Situation Report (17/10/21) 5 confirmed cases, three deaths, 369 contacts identified, and 308 contacts monitored.
October 13, 2021 – Democratic Republic of the Congo (DRC) health officials confirmed an Ebola vaccination campaign had launched in the North Kivu province where one confirmed Ebola case, plus three related suspected deaths, were recently reported. About 1,000 doses of the rVSV-ZEBOV Ebola vaccine and other medical supplies were delivered from the capital Kinshasa to Goma city in North Kivu. The DRC has more than 12,000 vaccine doses in Kinshasa that can be deployed if necessary.
October 10, 2021 – The WHO reported additional Ebola cases related to the recent DRC case of a 3-year-old boy. A cluster of three deaths (two children and their father) who were neighbors of the case. These three patients died on 14, 19, and 29 September 2021 after developing symptoms consistent with Ebola. However, none were tested for the virus. As of October 9th, a total of 148 contacts have been identified and are under follow-up by the local response team.
October 8, 2021 – A case of Ebola has been confirmed in the eastern Democratic Republic of the Congo, five months after the end of the most recent Ebola outbreak there. The child died on October 6th. It was not immediately known if the Ebola case was related to the 2018-20 outbreak that killed more than 2,200 people in eastern Congo or the flare-up that killed six people in 2021.
September 13, 2021 – A new study based in Sierra Leone concluded the Ebola vaccine regimen from Janssen – J&J. It was found well tolerated with no safety concerns in children aged 1–17 years and induced robust humoral immune responses, suggesting the suitability of this regimen for Ebola virus disease prevention in children.
August 31, 2021 – The government of Cote d’Ivoire has informed the WHO that a second laboratory has tested samples from a patient suspected of having Ebola and has found no evidence of the virus. Around a dozen WHO experts were mobilized to support the country’s efforts, and 5,000 Ebola vaccine doses which WHO had helped Guinea procure were sent from Guinea to Cote d’Ivoire.
August 23, 2021 – The WHO African region reported Ebola booster dose vaccinations in Sierra Leone following administration of the prime dose of the Johnson & Johnson Ebola vaccine in May 2021. Frontline health workers, practitioners of traditional medicines or traditional healers, and commercial motorbike riders who received the first dose are now given their second jab to maximize their protection against the disease.
August 17, 2021 – The WHO confirmed Cote d’Ivoire deployed 2,000 vaccine doses from Merck and around 3,000 vaccine doses manufactured by Johnson & Johnson – Janssen.
August 14, 2021 – The WHO Africa reported the Ministry of Health of Cote d’Ivoire today confirmed the country’s first case of Ebola since 1994. This came after the Institut Pasteur in Cote d’Ivoire confirmed the Ebola Virus Disease in samples collected from a patient hospitalized in Abidjan’s commercial capital after arriving from Guinea.
August 9, 2021 – The WHO confirmed ‘Marburg virus disease (MVD) is a highly virulent, epidemic-prone disease associated with high case fatality rates (CFR 24-90%). In the early course of the disease, the clinical diagnosis of MVD is difficult to distinguish from other tropical febrile illnesses because of the similarities in the clinical symptoms. Differential diagnoses to be excluded include Ebola virus disease, as well as malaria, typhoid fever, leptospirosis, rickettsial infection, and plague.’
June 15, 2021 – The Southwest National Primate Research Center at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the U.S. National Institutes of Health to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.
June 4, 2021 – Johnson & Johnson welcomed a new recommendation by the Strategic Advisory Group of Experts on Immunization for the WHO that supports the use of the Johnson & Johnson Ebola vaccine regimen both during outbreaks for individuals at some risk of Ebola exposure and preventively, in the absence of an outbreak, for national and international first responders in neighboring areas or countries where an outbreak might spread.
April 10, 2021 – The government of Sierra Leone and the WHO announced Johnson & Johnson had donated about 4,500 Zabdeno and Mvabea Ebola vaccines to Sierra Leone to help prevent any Ebola outbreak. The last Ebola outbreak in Sierra Leone was in 2016.
March 25, 2021 – Ohio Gov. Mike DeWine revealed health officials are monitoring 44 people who have returned from areas of Africa with active outbreaks of Ebola.
March 25, 2021 – Oregon public health officials announced they are monitoring four people who recently visited the West African countries of Guinea and the Democratic Republic of the Congo. Regions in each of these countries are currently experiencing outbreaks of Ebola virus disease. The Oregon Health Authority and local public health departments have been in contact with these individuals, considered “persons under monitoring” since they arrived in the state earlier in March 2021.
March 23, 2021 – The WHO African Region Tweeted Guinea Ebola outbreak Situation Report (22/03/21) 18 cases, nine deaths, 78 contacts, 82% monitored. And 3,905 people have been vaccinated.
March 13, 2021 – After a request from the Guinean authorities, Russia is considering supplying a domestic vaccine against the Ebola virus to the African country, reported TASS.
May 13, 2020 – BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines
The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials. In September 2019, BARDA awarded Sabin a development contract, valued at $128 million, and provided the initial funding award of $20.5 million. This second $20 million award will enable the manufacture and release of clinical vaccine material developed by ReiThera, a specialist in the development and cGMP manufacture of adenoviral vector vaccines. The funding will also support non-clinical studies to evaluate efficacy and immune response.
UPDATE 5: NOVEMBER 7, 2021: MARBURG GOES VIRAL ON INTERNET ONLY, YET. I’m happy awareness increases, it’s crucial. I’ve addressed this virus below, but not many had the patience to go through all text, and I kind of understand them, but there’s no easier way than reading. Here’s another angle to keep in sight when computing all this info:
UPDATE 4: OCTOBER 19 2021: THE FEARPORN CAMPAIGN TAKES SPEED AS IF THEY ARE TO RELEASE THIS SOON. IF YOU FALL FOR THEIR BRAINWASH, THEY HAVE NO REASON TO STOP.
And they’re still not running out of stupid ideas we can see through:
Oh, look who pushes the fear! Exactly who I would’ve expected:
Later update: In the meantime I’ve learned that Marburg (an Ebola relative) and Xinjiang fever, a Chinese relative of the Yellow Fever virus, are also top candidates, and that goes in line with the Fauci e-mails I highlighted below. I will be back with more details shortly. Almost certainly it will be some form of hemorrhagic fever, most likely to cover for injections side-effects on the blood stream.
UPDATE 2:
One month later, they’re starting to catch up and it’s still not too late to un-play it if this goes BOOM NOW!
By the end of last century, The Military has abandoned you and has joined Pharmafia and the super-rich elites in a plan to govern you with bioweapons and psy-ops. As I’ve said many times, Big Pharma and Big Tech are long gone, The Military BioTech Complex has been running the show for quite a while. This is just a chapter from that book, more to come if we get some love.
Canadian lab’s shipment of Ebola, Henipah viruses to China raises questions
Henipah and Nipah are interchangeable
Scientists at the National Microbiology Lab sent live Ebola and Henipah viruses to Beijing on an Air Canada flight March 31, and while the Public Health Agency of Canada says all federal policies were followed, there are questions about whether that shipment is part of an ongoing RCMP investigation.
Ebola and Henipah are Level 4 pathogens, meaning they’re some of the deadliest viruses in the world. They must be contained in a lab with the highest level of biosafety control, such as the one in Winnipeg.
Two months after that shipment, on May 24, the Public Health Agency of Canada (PHAC) referred an “administrative matter” to RCMP that resulted in the removal of two Chinese research scientists — Xiangguo Qiu and Keding Cheng — and several international students on July 5.
Both agencies have said repeatedly that public safety has not been at risk.
PHAC will not confirm if the March 31 shipment is part of the RCMP investigation.
Strict protocols
Several sources, who have asked to remain anonymous because they fear for their jobs, say the pathogens may have been shipped to the Chinese Academy of Sciences in a way that circumvented the lab’s operating procedures, and without a document protecting Canada’s intellectual property rights.
Researchers working at the National Microbiology Lab on cutting-edge, high-containment research are not allowed to send anything to other countries or labs without the intellectual property office negotiating and having a material transfer agreement in place, in case the material sent leads to a notable discovery.
A PHAC spokesperson did not confirm if this shipment included such an agreement.
However, Eric Morrissette said it’s “routine” for the lab to share samples of pathogens and toxins with partners in other countries to advance scientific work worldwide.
“All transfers of Risk Group 4 samples follow strict transportation requirements and are authorized by senior officials at the lab and the NML tracks and keeps electronic records of all shipments of samples in accordance with the HPTA. Agreements for the transfer of materials are determined on a case-by-case basis,” Morrisette wrote in an email statement.
“On the specific shipments to China earlier this year, we can confirm that we have all records pertaining to the shipment, and that all protocols were followed as directed by the above Acts and Standards.”
Xiangguo Qiu is head of the National Microbiology Lab’s Vaccine Development and Antiviral Therapies section in the Special Pathogens Program. She is responsible for the lab that works with Ebola. Her husband, Keding Cheng, is also a PHAC biologist.
After their security clearance was revoked and they were escorted from the lab, the University of Manitoba also cut ties with them and re-assigned Qiu’s graduate students, pending the RCMP investigation. No charges have been laid.
Neither scientist has responded to requests for comment, although some of their former colleagues say Qiu is not just a world-renowned scientist who helped develop a treatment for Ebola, but also a researcher with ethics and integrity.
Case raises questions
One question raised by this case is that of intellectual property protection, says Leah West, who practises, studies and publishes in the field of national security law and lectures at the Norman Paterson School of International Affairs.
“If China was leveraging these scientists in Canada to gain access to a potentially valuable pathogen or to elements of a virus without having to license the patent … it makes sense with the idea of China trying to gain access to valuable IP without paying for it,” she said.
West accepts PHAC’s assertion that public safety is not an issue, even though the viruses were transported on a commercial Air Canada flight.
However, she says the fact the RCMP is involved means there’s a legitimate concern.
“You don’t send a policy breach, a bureaucratic policy breach, to the RCMP to investigate unless you believe that that policy breach has resulted in a criminal offence or could have resulted in a criminal offence. So what is the criminal offence potentially here?” West said.
She said she hopes the lab and Health Canada are also doing an internal investigation.
“I think there will need to be an inquiry into the scientists to potentially see whether or not they were compromised or any elements of their work were compromised and that China gained illegal or improper access to Canadian intellectual property … to see what China may have gained access to without knowledge, prior to this incident,” West says.
Don’t ‘jump into any conclusions too quickly’
However, the deputy director of the University of Alberta’s China Institute is urging caution when it comes to making assumptions.
Jia Wang doesn’t dispute China has been involved in the past in espionage and intellectual property theft, but she says that country is making big investments in developing STEM (science, technology, engineering and mathematics) scholars and then putting that into innovation.
China has its own reasons to protect intellectual property because many new ideas are coming from there, Wang says.
She’s waiting to see what comes of the RCMP investigation of the lab in Winnipeg.
“As China observers, we’d like to perhaps gently remind people not to jump into any conclusions too quickly,” she said.
“It will be good to get to the bottom of this and see what might have gone wrong and what was the oversight and how can the procedures be improved or people involved can be reminded of how to adhere to the policies better.”
The shipment of the viruses took place at a time when relations between Canada and China have been strained over the arrest of a Huawei executive, at the request of the United States.
In retaliation, China has detained two Canadians and is boycotting Canadian canola and pork.
Because of the strained relationship between the two countries, and this case at the lab, Chinese-Canadian researchers and academics are starting to worry they may be singled out and targeted, Wang said.
“Certain assumptions are made or their loyalty to Canada is questioned in any way. And as multicultural as we are in Canada, we don’t want to see that.” – CBC, 2019
On December 19, 2019, the U.S. Food and Drug Administration announced the approval of Ervebo to prevent EVD caused by Zaire ebolavirus in individuals 18 years of age and older. This report, published by the U.S. CDC on January 8, 2021, summarizes the Advisory Committee on Immunization Practices (ACIP) recommendations for using the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the USA.
On July 1, 2020, the European Medicines Agency granted Johnson & Johnson Janssen’s Zabdeno and Mvabea Ebola vaccine therapy, a prime-boost vaccination approach for preventing infectious diseases. Janssen’s Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above.
CanSino Biologics’s Ad5-EBOV Ebola vaccine received approval in China in October 2017. Ad5-EBOV is an adenovirus type 5 vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. In addition, Ad5-EBOV is manufactured as a lyophilized powder, highly stable, and does not require storage at ultra-low temperatures. This feature renders it viable for use in resource-limited tropical areas.
The WHO published the revised Ebola Vaccine FAQ on January 11, 2020.
Henipaviruses belong to the family of paramyxoviruses. Two species have been identified to be zoonotic, causing disease in animals. These are the Hendra virus (HeV) and the Nipah virus (NiV). They produce severe and often fatal illness in humans and horses.
Samples from early Wuhan COVID-19 patients show the presence of genetically modified Henipah virus, an American scientist has found.
Henipah was one of the two types of viruses sent to China by Chinese-born scientists from a Canadian laboratory at the centre of a controversy over the firing of the scientists and collaboration with Chinese military researchers. It is not clear whether the virus found in the Chinese samples is related to the samples sent by the Canadian lab, which were shipped in late March 2019.
The finding was confirmed for The Epoch Times by another qualified scientist.
The evidence was first found by Dr. Steven Quay, a Seattle-based physician-scientist and former faculty member at the Stanford University School of Medicine, who looked at early COVID-19 samples uploaded by scientists at the Wuhan Institute of Virology (WIV) shortly after China informed the World Health Organization about the SARS-CoV-2 outbreak.
Chinese virologist Shi Zhengli is seen inside the P4 laboratory in Wuhan, China, on Feb. 23, 2017. (Johannes Eisele/AFP via Getty Images)
The samples from the patients, who reportedly were found to have the “unknown pneumonia” in December 2019, were uploaded to the genetic sequence database, GenBank, on the website of the U.S. National Institute of Health (NIH).
Quay says that while other scientists around the world were mostly interested in examining the genome of SARS-CoV-2 in the samples uploaded by the WIV scientists, he wanted to see what else was in the samples collected from the patients.
So he collaborated with a few other scientists to analyze sequences from the samples.
“We started fishing inside for weird things,” Quay told The Epoch Times.
What they found, he says, are the results of what could likely be contamination from different experiments in the lab making their way into the samples, as well as evidence of Henipah virus.
“We found genetic manipulation of the Nipah virus, which is more lethal than Ebola.” Nipah is a type of Henipah virus.
The Epoch Times asked Joe Wang, PhD, who formerly spearheaded a vaccine development program for SARS in Canada with one of the world’s leading pharmaceutical companies, to verify the finding. Wang is currently the president of NTD Television Canada, the sister company of The Epoch Times in Canada.
After examining the evidence, Wang said he was able to replicate Quay’s findings on the Henipah virus. He explains that the genetic manipulation of the virus was likely for the purposes of vaccine development.
Winnipeg Lab
The firing of Chinese-born scientist Xiangguo Qiu and her husband, Keding Cheng, from the National Microbiology laboratory (NML) in Winnipeg has been the subject of much controversy in Canada, with opposition parties pressing the government for more details on the case, and the government refusing to release information citing national security and privacy concerns.
Qiu and Cheng along with several Chinese students were escorted out of NML, Canada’s only Level 4 lab, in July 2019, amid a police investigation. The two scientists were formally fired in January 2021.
The Public Health Agency of Canada (PHAC), which is in charge of NML, said the termination was the result of an “administrative matter” and “possible breaches of security protocols,” but has declined to provide further details, citing security and privacy concerns.
House Speaker Anthony Rota admonishes Public Health Agency of Canada President Iain Stewart in the House of Commons on June 21, 2021, for failing to provide documents related to the firing of two scientists from the National Microbiology Laboratory in Winnipeg. (The Canadian Press/Sean Kilpatrick)
During her time at NML, Qiu travelled several times in an official capacity to WIV, helping train personnel on Level 4 safety. The Globe and Mail later reported that scientists at NML have been collaborating with Chinese military researchers on deadly pathogens, and that one of the Chinese military researchers worked at the high-security Winnipeg lab for a period of time.
Documents and emails released by PHAC show that the shipment of Henipah and Ebola samples was done with the permission of NML authorities.
In one of the emails sent in September 2018, David Safronetz, chief of special pathogens at PHAC, informs then-head of NML Matthew Gilmour and other lab administrators about the request from WIV for the shipment of the samples, saying “I trust the lab.”
In response, Gilmour asks about the nature of the work that will be done at the Wuhan lab, and why the lab doesn’t get the material from “other, more local labs.” He also tells Safronetz that it’s “good to know that you trust this group,” asking how NML was connected with them.
In his reply, Safronetz doesn’t specifically say what the samples will be used for in China, but notes they will only be sent once all paperwork and certification is completed. He also says the WIV is requesting the material from NML “due to collaboration” with Qiu.
He adds, “Historically, it’s also been easier to obtain material from us as opposed to US labs. I don’t think other, closer labs have the ability to ship these materials.”
Gilmour resigned from his position at NML in May 2020 and joined a UK-based bioresearch company.
MPs have asked NML management why shipment of the samples was allowed and whether they knew if China performs any Gain of Function (GoF) research at WIV. GoF research involves increasing the lethal level (virulence) or transmissibility of pathogens.
NML’s acting scientific director general Guillaume Poliquin told MPs during a parliamentary committee meeting on March 22 that the lab only sent the samples to WIV after receiving assurance that no GoF research would take place.
Conservative MP John Williamson pressed for more answers, saying the word of the state-run Chinese lab can’t be trusted as the Chinese regime “has a history of theft and lies.”
The issue of GoF research at WIV has been a point of contention in the United States between lawmakers and Dr. Anthony Fauci, NIH’s head of the National Institute of Allergy and Infectious Diseases, whose organization has funded research (through EcoHealth Alliance) on coronaviruses at the Wuhan lab. U.S. Sen. Rand Paul says published work from WIV on coronaviruses shows the lab is conducting GoF research, a charge Fauci denies.
The P4 laboratory on the campus of the Wuhan Institute of Virology in Wuhan, China, on May 13, 2020. (Hector Retamal/AFP via Getty Images)
The Epoch Times sought comment from PHAC, including as to how the agency addressed issues of intellectual property and the development of any products such as vaccines with WIV, but didn’t hear back by time of publication.
Despite repeated requests by opposition parties for more details related to the firing of the two NML scientists, the Liberal government has refused to provide records, saying there are national security and privacy concerns.
After the House of Commons issued an order for the government to disclose the information, the government took the Speaker of the House to court to obtain confirmation from a judge that it can withhold the documents. The government later dropped its court case once Prime Minister Justin Trudeau called an election and Parliament was dissolved. – Epoch Times
UPDATE 3: I FOUND CREDIBLE SOURCES FOR MOST OF DR. ARYANA LOVE’S EXPLOSIVE CLAIMS BELOW:
I didn’t have an in depth look at all her sources, I can’t have a final 100% verdict, but I did more than a glance and no lies detected. You can review her blog post yourself HERE. This might be the closure to this report and the start for another.
OBAMA: EBOLA RESPONSE A TRIAL RUN FOR A POTENTIAL AIRBORNE VIRUS THAT MIGHT HIT SOON (2014)
BONUS
This is from 2014, but the story goes a way long back. And forward. Let’s not forget Putin is a Davos regular since before he became such a literal czar.
WHERE IT’S AT EXACTLY TWO YEARS LATER (SEPT. 2023)
meanwhile, we found out that…
In March 2015, a CureVac investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary mRNA platform… n July 2020, Tesla, Inc CEO Elon Musk announced via Tweet that Tesla and CureVac had reached an agreement to produce portable “RNA microfactories” based on this technology to manufacture CureVac’s COVID-19 vaccine candidate. CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks. At approximately the same time, Tesla and CureVac filed a joint patent on the technology. In August, Musk reviewed the project with Curevac while in Germany.
How much of the tsunami is fabricated in Musk’s factories?
So we’re back at:
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
I had to pull out the colored crayons as the world is a kindergarten.
LATER UPDATE: VIDEO VERSION READY, IT GOES EVEN DEEPER…
This is your virus, one of the versions, but it has only proven to exist in form of a salad of four characters shaped as a genetic code. SOURCESOURCE
When you ask about virus Gold-Standard evidence, aka purification and isolation as per Koch’s Postulates, they give you “cultures”. That’s like saying you discovered a new species of primate but you can only show a jungle.
That letter salad was fed into a computer program which generated the formulations for injections in mere hours, as the industry bragged:
Proving the virus is bullshit had never been easier:
Now, the more you investigate other viruses, the more you have similar surprises. And that goes for 99% of what you hold true.
Especially the slavery
Don’t trust what I say, research it.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
You know how every piece of a broken hologram becomes a smaller hologram and projects the whole thing? There.
I could waste more of your time with blah, but let’s be honest here.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
New from your favorite coincidence-theories magazine: There’s two timelines here that seem to meet somewhere in the recent past.
#1
CDC has just announced retiring Covid PCR tests, starting from 2022 because they can hardly tell Covid from Flu. Where Covid is caused by a virus that no one has seen in full, purified and isolated form:
We all knew that, last summer I even made a meme where I coined the term “PCRdemic”. But just imagine how “based” their Delta Variant detection must be then! And someone was found already preparing for this, while the plebs are shocked by the admission or not even processing it.
#2
Only weeks before this announcement, media just whispered about the new unholy alliance between Soros and Gates, who suddenly decided to buy together a major UK Covid test maker.
This alliance has a legal and formal representation as the Global Access Health (GAH), something very similar to GAVI, but focused on pillaging Africa, South America and South-Asia.
Only months before this announcement, Soros and Gates became some of the most downvoted personalities in the Northern Hemisphere, with very little competition and no benefits for the public image of the Great Reset. Meanwhile, I was writing on HOW BILL GATES AND BANKSTERS GANGED UP TO TAKE MOROCCO. AND NOW ARE RUINING IT..
Only years before that, teachers and intellectuals in US were marching against Gates’ medical and food machinations in Africa.
And so forth… as far as we’re willing to dig we find ourselves entrapped and enslaved by the same inbred class that wages now a class war against the lower classes under various guises.
Every conspiratorial correlation comes with two options: conspiracy theory (causative) or coincidence theory (non-causative). I’m too experienced to hesitate here.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Much like the Fed, CDC isn’t a government agency, it’s more like a prototype of today’s PPP’s (Private-Public Partnerships) used by the WEF to siphon public wealth into private pockets and subvert the political self-determination of the people.
One way for CDC to attract funds is their Foundation. And we can’t follow the money if we don’t even know who the sponsors are. If you had difficulties before in finding them, though I can’t imagine one, now you have no excuse, you just need to CLICK HERE to find out more about the conflict of interests in which Pharmafia thrives like a baby in the amniotic juice. Removing that womb would terminate this vile genocidal cartel. There’s more than just that page, but that’s where you start YOUR OWN RESEARCH.
Interestingly, the CDC Foundation self-portrait looks very much like Klaus Schwab:
“The CDC Foundation is an independent nonprofit and the sole entity created by Congress to mobilize philanthropic and private-sector resources to support the Centers for Disease Control and Prevention’s critical health protection work.
We are a catalyst for unleashing the power of collaboration between CDC and philanthropies, private entities and individuals to protect the health, safety and security of America and the world.
The government has unique capacities as well as limitations. The same is true for the private and philanthropic sectors. We believe that people, groups and organizations have greater positive impact and can accomplish more collectively than individually. By aligning diverse interests and resources and leveraging all parties’ strengths, our focused collaborations with private and philanthropic partners help create greater impact than any one entity can alone. Your support saves and improves lives—right now and in the future.
Thanks to our donors, we have launched approximately more than 1,200 health protection programs and raised over $1.2 billion to support CDC’s work over the past two decades. To keep people healthy, safe and secure, we managed hundreds of programs in the United States and in more than 140 countries.” – SOURCE
Now, to make my point, I just need to highlight some of the names found there, for your later references. These are some of the people who home-detain, muzzle and inject us. Interestingly, most of them are also partners in the World Economic Forum.
Before fusing humans with technology, the Schwaborg has fused Pharmafia with Big Tech, mainstream media and the Governments. These are not independent voices confirming one another, they’re the same entity, like the Borg (and I’ll prove later that Star Trek’s Borg is not just science-fiction entertainment).
If your nutritionist has a McDonalds badge, you have no nutritionist. Btw, many US and UK hospitals, maybe in other countries too, host McDonalds restaurants. Same people.
Some things are not meant to be businesses, public health is one of them.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Less decency and honesty in science than in politics, these days. I didn’t think there’s a few levels below politics.
You know when your juice bottle says “100% orange” and the small prints say it’s just 50% of fruit “concentrate”? They should be arrested for that. Now concentrate on this:
If I were to sum it up in words, I’d quote the source of this revelation:
“It is like saying that there were 700 men and 127 women studied and only a small percent got pregnant. Well, from the start 700 could not have gotten pregnant in the first place.”
Wheatley has just tipped LifeSite News on this, and I immediately did my own verification, anyone can and should do it. The result became the cover image for this article, which really is the beginning and the end of the debate, sums up Covidiocracy for me.
The data was collected and “arranged” by a team of “CDC experts” who published it in the New England Journal of Medicine in April 2021. It remained overlooked until mid July, when NEJM followed up with a shameless editorial that questioned nothing, just furthered the lie. And that’s when the small prints caught some diligent eyes and went to become our big headline today, as they deserve. Evil is in the small prints, again, that’s why they hate you when you carefully read inserts and labels.
This is Covidiocracy Science for you, this is the highly esteemed New England Journal of Medicine, up there, close to the British Medical Journal as reputation.
Mind that 82% is 3x the normal rate. All that extra dead babies blood is on the hands of CDC, NEJM and the likes of.
UPDATE:
A reader pointed out that Jeffrey Jaxxen too blew the lid on this, on Del Bigtree’s show, a few days back, and they reached precisely the same conclusion. BUT I noticed one very interesting detail that Del brought up and single-handedly proves intention in this fake narrative: The study hast no less than 54 authors. There is no chance in heaven and hell that they all missed this. If it’s not by mistake, it’s by intention.
This are just my highlights from the show, the full thing is linked above
And we really have to extrapolate this example to all walks of life, because they are all infected with the same corruption. None as blatantly as science, but you still can’t rely on anything you can’t research and verify yourself.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Sometimes my memes are 3D. And you can own them. Or send them to someone. You can even eat some of them. CLICK HERE
Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.
The Anti-Defamation League in the US is supportive of Prescott Bush and the Bush family. In a statement last year they said that “rumours about the alleged Nazi ‘ties’ of the late Prescott Bush … have circulated widely through the internet in recent years. These charges are untenable and politically motivated … Prescott Bush was neither a Nazi nor a Nazi sympathiser.” However, one of the country’s oldest Jewish publications, the Jewish Advocate, has aired the controversy in detail.
Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.
Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.
Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.
Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.
What’s Bayer been up to lately? We find out from their website:
The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.
The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.
All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.
The implications across the life sciences can be enormous:
For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.
The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.
Total number of CRISPR patent applications worldwide per year from 1984 to 2018.
Fueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.
World Economic Forum, Bio-Innovation Dialogue Initiative
As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0
The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.
Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?
The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.
In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.
Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.
Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.
Advancing genetic solutions for a sustainable future (1)PreviousNext
Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?
With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.
$1 Billion
Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.
Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.
Leaps is our way of thinking big.
Werner Baumann, CEO of Bayer AG
Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.
Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.
We face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.
Jürgen Eckhardt, Head of Leaps by Bayer
Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.
The Leaps by Bayer investment portfolio includes more than 35 companies.
At least that’s what Bayer says. All I know is that they’re still running the show.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
We gave up on our profit shares from masks, if you want to help us, please use the donation button! We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness. Get it here!
Fueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.
SILVIEW.media 